Pneumonia is the leading cause of morbidity and mortality, particularly in old adults. The incidence and etiologic distribution of community-acquired pneumonia is variable both geographically and temporally, and epidemiology might evolve with the change of population characteristics and vaccine uptake rates. With the increasing prevalence of chronic medical conditions, a wide spectrum of healthcare-associated pneumonia could also affect the epidemiology of community-acquired pneumonia. Here, we provide an overview of the epidemiological changes associated with community-acquired pneumonia over the decades since pneumococcal conjugate vaccine introduction.
INTRODUCTION
Pneumonia is the leading infectious disease and is ranked the fourth most common cause of death in South Korea as of 2017 [1] . Globally, three million people die annually due to pneumonia, exceeding all other infectious causes including tuberculosis, malaria, and human immunodeficiency virus (HIV) infection [2] . With the increase in elderly population with chronic disease, long-term care facilities (LTCF) have expanded in South Korea in the recent decade, and this increase in elderly people living in LTCF could be contributing to the rise in pneumonia-related morbidity and mortality.
Prior to 2005, pneumonia was classified as either community-acquired pneumonia (CAP) or hospital-acquired pneumonia (HAP). Since 2005, healthcare-associated pneumonia (HCAP) was first incorporated into the HAP guidelines of the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA), considering that HCAP patients might be at high risk for multi-drug resistant (MDR) pathogens through repeated contact with the healthcare system [3] . However, HCAP was removed from the revised HAP guidelines again in 2016, and was supposed to be included in the upcoming CAP guidelines [4] . Similar to [18] 1997 US ≥65 years: 1,830 10. 6 Inclusion Exclusion ICD code Retrospective Jackson et al. [16] 1998-2001 US ≥65 years: 2,840 3.6 Inclusion Inclusion ICD code Retrospective Griffin et al. [14] 1997-1999 US 18-64 years: 107-336 NA Inclusion Exclusion ICD code Retrospective ≥65 years: 1,293-5,697 Lovering et al. [19] 1994-1996 UK 16-59 years: 52-106 18.9 Inclusion Inclusion Physician assessment Prospective ≥60 years: 275-720 Millett at al. [20] 1997-2005 UK ≥65 years: 630-793 NA Inclusion Inclusion ICD code Retrospective Monge et al. [21] 1995-1996 Spain <65 years: 93 <65 years: 2.7 Inclusion Exclusion ICD code Retrospective ≥65 years: 523 ≥65 years: 11.6 Gutierrez et al. [15] 1999 among adults. Since the introduction of pediatric PCV vaccination in national immunization programs (NIPs) in several countries, the incidence of invasive pneumococcal disease (IPD) was substantially decreased in both children and adults [26, 27] . However, although lots of studies were conducted to evaluate the incidence of CAP since the introduction of PCVs, indirect effects on adult CAP have not been conclusively determined [1, 2, 13, 14, 17, 20, [22] [23] [24] [25] [28] [29] [30] [31] [32] [33] . Previous reports in the United States have suggested that the incidence of hospitalized CAP among older adults showed a significant reduction in the last decade [14, 25, 31] . On the other hand, other studies have not shown any significant decrease in CAP rate in adults [20, 34] . These inconsistent results might be related to the diverse degree of indirect herd effect on older adults with respect to PCV coverage rates and time interval following PCV NIP implementation.
The case-fatality rate (CFR) of CAP has been published much more than those presented in table 1. Overall CFR ranged from 2.5% to 20%, reaching up to 50% in patients admitted to intensive care unit [35, 36] . CFR is influenced by several factors including age, sex, treatment regimen, vaccination status, and underlying comorbidities [37] . Although varied by country, approximately 10% of patients required intensive care, and 14% (median) died among hospitalized patients with CAP [38] .
ETIOLOGIC DISTRIBUTION OF CAUSATIVE PATHOGENS IN COMMUNITY-ACQUIRED PNEUMONIA
Because the causative pathogen of CAP is unknown on initial presentation, it is important to know the distribution of CAP etiologic agents for the selection of appropriate empirical antibiotics. Streptococcus pneumoniae has been recognized as the most common identifiable pathogen of CAP, followed by Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, Mycoplasma pneumoniae, and Chlamydophila pneumoniae in varying order ( Table 2) . Traditionally, causative agents of CAP were identified using conventional culture methods, so microorganisms were identified in less than 30% of CAP cases during the pre-PCV7 period [39] [40] [41] [42] [43] . With advances in serological and molecular diagnostic tests, the diagnostic yield has improved by up to 40-50%, yet around 50% of CAP pathogens are still unidentified ( Table 2 ) [7, [44] [45] [46] [47] . Prior antibiotic use is one of the important reasons for test-negative results. It is unclear to what degree viral pathogens and oral streptococci contribute to the development of pneumonia, and these are points to be further clarified in the future.
Among CAP cases caused by identified bacterial pathogens, S. pneumoniae is the most important causative species, accounting for 26.9-69.4% of pneumonia cases in South Korea ( Table 2 ) [48] , and the proportion of pneumococcal pneumonia was higher in studies confined to older adults [7, 49] . However, in a study of severe CAP cases admitted to intensive care units (ICUs), S. aureus infection was more common compared to S. pneumoniae (37.8% vs. 13.5%) [46] . Etiologic distribution might be affected by disease severity, age, and underlying medical conditions. Although IPDs were already reported as markedly decreased in both children and adults in the PCV13 era, data on pneumococcal CAP is still insufficient [50, 51] . The introduction of PCVs was expected to affect the etiologic distribution of CAP; however, significant change was not observed after the introduction of the pediatric PCV7 conjugate vaccine [5, 49, [52] [53] [54] [55] [56] . Even in the early period of PCV13 use, S. pneumoniae still remained as the predominant https://icjournal.org https://doi.org/10.3947/ic.2018.50.4.287 [7, [44] [45] [46] [47] . Similarly, in the etiology of pneumonia in the community study conducted in the United States during the early PCV13 period (2011-2012), S. pneumoniae was the most common causative pathogen of community-acquired bacterial pneumonia (30.1%, 115 cases), followed by S. aureus (9.7%, 37 cases) among the total 382 bacterial pneumonia cases [17] . Considering that about 65% of pediatric PCV13 immunization is required to expect a herd effect in adults and a seven year time period may be required to get the maximal herd effect from childhood immunization, subsequent studies are required to see the PCV13 herd effect [57, 58] ; however, there are several unpredictable uncertainties. First, it is not clear whether pediatric herd effect is enough to decrease non-invasive pneumococcal pneumonia in adults, not confined to IPDs. Second, depending on the degree of serotype replacement, the disease burden of pneumococcal pneumonia would be either persistent or decreased.
Evolving epidemiology of pneumonia

COMPARISON OF ETIOLOGIC DISTRIBUTION BETWEEN COMMUNITY-ACQUIRED PNEUMONIA VS. HEALTHCARE-ASSOCIATED PNEUMONIA
During the early 2000s, several studies in the United States reported a high prevalence of MDR pathogens including methicillin-resistant S. aureus (MRSA) and Pseudomonas aeruginosa in HCAP cases, who had recent contact with healthcare systems through nursing homes, hemodialysis, chronic wound care, or recent hospitalization as examples [59, 60] . Based on this evidence, the 2005 ATS/IDSA guidelines for nosocomial pneumonia included recommendations for HCAP treatment, suggesting empirical coverage of MDR pathogens [3] . Since then, subsequent studies were conducted in South Korea, Japan, and Spain, but most studies showed that S. pneumoniae is the most common causative agent of HCAP, similar to CAP (Table 3 ) [5-9, 44-46, 49, 54, 55, 61-65] . In addition, although the proportion of MDR pathogens is higher in HCAP, some studies revealed indistinguishable etiologic distribution of causative agents between HCAP and CAP [5] [6] [7] [8] [9] . Prior meta-analysis suggested that higher mortality of HCAP might not be associated with higher frequency of resistant pathogens [66] . Moreover, empirical antibiotic therapy based on HAP guidelines did not show better clinical outcomes compared to CAP regimen, and resulted in higher mortality with inadequate coverage for atypical pathogens in some studies [67] [68] [69] . Accordingly, HCAP treatment will be covered in the next revised ATS/IDSA CAP guidelines. Given that the HCAP population is heterogeneous and overlaps with that of CAP and HAP, HCAP needs to be further subclassified, and empirical antibiotic therapy for HCAP should be stratified based on the risk of MDR infection in each subgroup.
Since the introduction of PCV13, community-acquired pneumococcal pneumonia was expected to gradually decrease. In comparison, the disease burden of pneumococcal pneumonia might be persistent among at-risk HCAP populations particularly residing in LTCF with missed opportunity of vaccination [70] , as pneumococcal pneumonia outbreaks have been reported among unvaccinated nursing home residents [71, 72] . In some studies conducted in Japan, the proportion of pneumococcal pneumonia in HCAP was similar or rather higher compared to that of CAP (Table 3) [6, 8, 9] . The concerning point is that MDR S. pneumoniae might be transmitted among LTCF residents with repeated antibiotic exposure. Actually, levofloxacin and ceftriaxone-resistant pneumococcal HCAP cases were recently https://icjournal.org https://doi.org/10.3947/ic.2018.50.4.287
Evolving epidemiology of pneumonia Mycoplasma pneumoniae (0.0) Jeong et al. [5] 2008-2010 year/≥18 years Streptococcus pneumoniae (48. Escherichia coli (7.5) Mycoplasma pneumoniae (3.5) Mycoplasma pneumoniae (0.6) Maruyama et al. [9] 2009-2011 year/≥18 years Streptococcus pneumoniae (58. Haemophilus influenzae (5.6) Klebsiella pneumoniae (3.8) Klebsiella pneumoniae (6.2) Pseudomonas aeruginosa (1.9) Pseudomonas aeruginosa (11.3) Escherichia coli (1.9) Escherichia coli (3.6) Mycoplasma pneumoniae (20.8) Mycoplasma pneumoniae (6.7) Kosai et al. [8] 2009 Haemophilus influenzae (8.6) Pseudomonas aeruginosa (2.9) Pseudomonas aeruginosa (6.9) Enterobacteriaceae (7.0) Enterobacteriaceae (10. Comparison between community-acquired pneumonia vs. nursing home-acquired pneumonia. [73] [74] [75] and these MDR pneumococcal pneumonia cases were related to underlying neurological diseases and LTCF residence [73] [74] [75] . Pneumococcal disease burden among these high-risk populations should be monitored, and targeted vaccination strategy could be considered.
CONCLUSIONS
In this review, we summarized the incidence, CFR, and etiologic distribution of CAP since the introduction of PCV use. The incidence and etiologic distribution of this disease might be variable based on study population characteristics (density and age distribution), vaccine uptake rate, and case definitions as whether to include HCAP in the analysis. In the future, pneumonia-related morbidity and mortality could increase with our increasing aged population, and the proportion of HCAP might be higher with the rising prevalence of coexisting medical conditions. The current HCAP definition should be better clarified and further categorized to avoid overtreatment or undertreatment for MDR pathogens. Considering recent reports of MDR pneumococcal HCAP cases in South Korea,
